V. Naini

发表

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

N. Agarwal, D. Ye, A. Bjartell, 2019, The New England journal of medicine.

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

P. Kantoff, S. Larson, M. Morris, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.

E. Basch, N. Agarwal, D. Cella, 2019, The Lancet. Oncology.

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

F. Zhou, Yinghao Sun, D. Ye, 2017, Asian journal of urology.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, J. Carles, K. Miller, 2015, The Lancet. Oncology.

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

F. Saad, C. Sternberg, P. Mainwaring, 2014, The Lancet. Oncology.

753OFINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY.

F. Saad, K. Miller, C. Sternberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study

A. Santiago-Walker, D. Papantoniou, A. Necchi, 2022, European urology open science.

757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status

M. Monga, A. Santiago-Walker, D. Papantoniou, 2020 .

Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.

F. Saad, C. Sternberg, P. Mainwaring, 2013 .

TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)

C. Sternberg, T. Lebret, A. Merseburger, 2016 .

Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

A. Wyatt, N. Agarwal, F. Feng, 2019, Annals of Oncology.

Phase II clinical trial of bexarotene gel 1% in psoriasis.

D. Breneman, V. Stevens, P. Sheth, 2007, Journal of drugs in dermatology : JDD.

Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.

H. Nishiyama, V. Master, N. Vasdev, 2023, Journal of Clinical Oncology.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, J. Carles, K. Miller, 2015, The Lancet. Oncology.

Association of Radiographic Progression-Free Survival (RPFS) Adapted from Prostate Cancer Working Group 2 (PCWG2) Consensus Criteria (APCWG2) with Overall Survival (OS) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC): Results from COU-AA-302

S. Larson, M. Morris, H. Scher, 2012 .

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

F. Saad, C. Sternberg, P. Mainwaring, 2014, The Lancet. Oncology.